drugset
drugset / Trial / NCT05579431

A Phase 1, First-in-human Study of VX-634

NCT05579431 ↗

Phase 1 Completed 127 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.

Timeline

Start
2022-10-13
Primary completion
2023-05-24
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-634 Unknown — Oral

Indications

alpha 1-antitrypsin deficiency